Environmental Tectonics Corporation (ETC) announced an 8.6% increase in net sales to $18.3 million for the second quarter of fiscal 2027, driven by strong growth in Environmental Test and Simulation Systems and Advanced Disaster Management Simulators. However, net income from continuing operations declined by 19.7% to $1.2 million, impacted by lower gross profit margins and the sale of its Polish subsidiary, ETC-PZL Aerospace Industries. The company completed the sale of ETC-PZL and entered a 10-year cooperation agreement with the buyer, maintaining a supplier relationship. Operating income also fell 17.7%, reflecting higher costs despite increased sales. ETC's outlook includes focusing on its core Aerospace and Commercial/Industrial Systems segments while managing the transition post-sale.
Environmental Tectonics Corporation's fiscal 2027 Q2 results provide context for readers. Of 135 Industrials-sector US stocks on Pluang, 46 rose and 88 fell as of Oct 20, 2026 03:01 WIB. Notable movers include American Airlines Group Inc (AAL) at USD 11.87 with 100% buy orders, Virgin Galactic Holdings, Inc. (SPCE) at USD 2.35 also with 100% buy orders, and Honeywell Aerospace Inc. (HONA) at USD 162.74 with 100% sell orders.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
